Browse > Article
http://dx.doi.org/10.4333/KPS.2004.34.5.419

Bioequivalence of Kuhnil Propiverine Hydrochloride Tablet to BUP-4 Tablet (Propiverine Hydrochloride 20 mg)  

Cho, Hea-Young (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Park, Eun-Ja (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Kang, Hyun-Ah (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Baek, Seung-Hee (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Kim, Se-Mi (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Park, Chan-Ho (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Oh, In-Joon (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Moon, Jai-Dong (Medical School, Chonnam National University)
Lee, Yong-Bok (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
Publication Information
Journal of Pharmaceutical Investigation / v.34, no.5, 2004 , pp. 419-425 More about this Journal
Abstract
The purpose of the present study was to evaluate the bioequivalence of two propiverine hydrochloride tablets, BUP-4 (Jeil Pharm. Co., Ltd.) and Kuhnil Propiverine Hydrochloride (Kuhnil Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The propiverine release from the two propiverine hydrochloride formulations in vitro was tested using KP VIII Apparatus II method with a variety of dissolution media (pH 1.2, 4.0, 6.8 buffer solutions, water and blend of polysorbate 80 into pH 6.8). Twenty six healthy male subjects, $23.73{\pm}2.79$ years in age and $67.04{\pm}7.93\;kg$ in body weight, were divided into two groups and a randomized $2\;{\times}\;2$ cross-over study was employed. After one tablet containing 20 mg as propiverine hydrochloride was orally administered, blood was taken at predetermined time intervals and the concentrations of propiverine in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t,\;C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the BUP-4 were 0.17%, 7.98% and 4.55% for $AUC_t,\;C_{max}\;and\;T_{max}$. respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) $(e.g.,\;log(0.88){\sim}log(1.l2)\;and\;log(0.90){\sim}log(1.l5)\;for\;AUC_t\;and\;C_{max},\;respectively)$. Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Kuhnil Propiverine Hydrochloride tablet was bioequivalent to BUP-4 tablet.
Keywords
Propiverine; BUP-4; Kuhnil Propiverine Hydrochloride; Bioequivalence; HPLC;
Citations & Related Records
연도 인용수 순위
  • Reference
1 G. Franke, F. Schnabel, A. Weinbrenner, K. Richter, T. Gramatt and W. Siegmud, Steady-state disposition of the bladder spasmolytics propiverine is circadian time dependent in man, Eur. J. Clin. Pharmacal., 56, 93(26) (2000)
2 A. Wengler, T. Schneider, M. Zschiesche and W. Siegmud, Undersuchungen zwm metabolismus des blasenspasmolytikums propiverine (mictonorm) beim menschen, Pharmazie., 43, 652-653 (1988)
3 K. Hanaoka, T. Kugimiya and Y. Inada, Phase I study of propiverine hydrochloride. The 2nd report: repeated oral dosing study, Jpn. J. Clin. Pharmacol. Ther., 21, 567-568 (1990)   DOI
4 P. Meisel, S. Langner and W. Siegmud, In-vivo binding of propiverine hydrochloride and some of its metabolites to serum albumin in man, J. Pharm. Pharmaco., 49, 270-272 (1997)   DOI   ScienceOn
5 Martindale, The complete drug reference, 32 edition 1999, 61 (1999)
6 Japan pharmaceutical information center : Drug in Japan - Ethical drugs, 25 edition, 1894-1896 (2002)
7 I. Komoto, K. Yoshida, E. Matsushima, K. Yamashita, T. Aikawa and S. Akashi, Validation of a simple liquid chromatography-tendem mass spectrometric method for the determination of propiverine hydrochloride and its N-oxide metabolism in human plasma, J. Chromatagr. B; 799(1), 141-147 (2004)   DOI   ScienceOn
8 H. Madersbacher and G. M$\ddot{u}$rtz, Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic), World. J. Urol, 19, 324-335 (2001)   DOI   ScienceOn
9 K.O. Haustein and G. Huller, On the pharmacokinetics and metabolism of propiverine in man, Eur. J. Drug Metab. Pharmacokinet., 13(2), 81-90 (1988)   DOI
10 R. Walter, C. Ullmann, D. Th$\ddot{u}$mmler and W. Siegmund, Influence of propiverine on hepatic microsomal cytochrome P450 enzymes in male rats, Drug Metab. Dispos., 31, 714-717 (2003)   DOI   ScienceOn
11 Food and Drug Administration (FDA): Guidance for Industry; Waiver of in vivo bioavailability and bioequivalence study for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Center for Drug Evaluation and Research (CDER), August (2000)
12 염산프로피베린 제제의 생물학적동등성시험 지침, 식품의약품안전청 독성연구원 의약품동등성평가과 (2003. 1)
13 식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험기준 (2002. 11. 22)
14 식품의약품안전청 고시 제 1999-67호, 의약품임상시험관리기준 (2000. 1. 4)